ArticleMedComm2026
Type 2 Diabetes Mellitus Modifies the Prognostic Value of LDL Particle Size in Statin-treated Patients With Coronary Artery Disease: A Large-scale Cohort Study.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LDL-cholesterol (LDLC) to apolipoprotein B (ApoB) ratio is an accessible and reliable proxy for the LDL-particle size. The aim of the present study was to investigate whether type 2 diabetes mellitus (T2DM) modulates the prognostic value of LDL-C/ApoB ratio in statin-treated patients with coronary artery disease (CAD). The study included 21,382 patients with CAD who had received statin therapy at baseline with a median follow-up of 3.1 years. The primary endpoint was major adverse cardiac events (MACE), including all-cause mortality, non-fatal myocardial infarction (MI), and ischemia-driven revascularization. Higher LDL-C/ApoB level (≥1.2) was associated with a decreased risk of MACE in the T2DM group (adjusted HR: 0.81, 95% CI: 0.69-0.96). A stepwise increase of 0.1 unit in LDL-C/ApoB ratio was associated with a 5% decrease for MACE only in the T2DM group. Among participants without T2DM, there was no clear association between LDL-C/ApoB and MACE (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.